Literature DB >> 20924362

Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.

Hyunjung Baek1, Hiroaki Uchida, Kyungok Jun, Jae-Hong Kim, Masahide Kuroki, Justus B Cohen, Joseph C Glorioso, Heechung Kwon.   

Abstract

The safety and efficacy of viral therapies for solid tumors can be enhanced by redirecting the virus infection to tumor-specific cell-surface markers. Successful retargeting of herpes simplex virus type 1 (HSV-1) has been achieved using vectors that carry a modified envelope glycoprotein D (gD) engineered to interact directly with novel receptors. In addition, soluble bridging molecules (adapters) have been used to link gD indirectly to cell-specific receptors. Here, we describe the development of an adapter connecting gD to the common tumor antigen carcinoembryonic antigen (CEA). The adapter consisted of a CEA-specific single-chain antibody fused to the gD-binding region of the gD receptor, herpes virus entry mediator (HVEM). We used this adapter in combination with a vector that is detargeted for recognition of the widely expressed gD receptor nectin-1, but retains an intact binding region for the less common HVEM. We show that the adapter enabled infection of HSV-resistant Chinese hamster ovary (CHO) cells expressing ectopic CEA and nectin-1/CEA-bearing human gastric carcinoma cells that are resistant to the vector alone. We observed cell-to-cell spread following adapter-mediated infection in vitro and reduced tumor growth in vivo, indicating that this method of vector retargeting may provide a novel strategy for tumor-specific delivery of tumoricidal HSV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924362      PMCID: PMC3048173          DOI: 10.1038/mt.2010.207

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  53 in total

1.  Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry.

Authors:  Florent C Bender; J Charles Whitbeck; Huan Lou; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 2.  Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

Authors:  Ta-Chiang Liu; Evanthia Galanis; David Kirn
Journal:  Nat Clin Pract Oncol       Date:  2007-02

3.  Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter.

Authors:  M H Verheije; T Würdinger; V W van Beusechem; C A M de Haan; W R Gerritsen; P J M Rottier
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.

Authors:  T Würdinger; M H Verheije; K Broen; B J Bosch; B J Haijema; C A M de Haan; V W van Beusechem; W R Gerritsen; P J M Rottier
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors.

Authors:  Toshihiro Tanaka; Jianhua Huang; Sachie Hirai; Motomu Kuroki; Masahide Kuroki; Naoki Watanabe; Kei Tomihara; Kazunori Kato; Hirofumi Hamada
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

6.  Soluble V domain of Nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D.

Authors:  Heechung Kwon; Qing Bai; Hyun-Jung Baek; Kelly Felmet; Edward A Burton; William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  Inactivation of herpes simplex type 1 gene vector on immobilized metal affinity chromatography: oxidative damage by hydroxyl free radicals and its prevention.

Authors:  Canping Jiang; Mohammad Ataai; Ali Ozuer; David Krisky; James Wechuck; Soraya Pornsuwan; Fazard Pourarian; Joseph C Glorioso
Journal:  Biotechnol Bioeng       Date:  2006-09-05       Impact factor: 4.530

8.  Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection.

Authors:  Marianna Tsvitov; Arthur R Frampton; Waris A Shah; Steven K Wendell; Ali Ozuer; Zoher Kapacee; William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Virology       Date:  2006-12-08       Impact factor: 3.616

9.  Nectin-1/HveC Mediates herpes simplex virus type 1 entry into primary human sensory neurons and fibroblasts.

Authors:  Scott A Simpson; Michael D Manchak; Elizabeth J Hager; Claude Krummenacher; J Charles Whitbeck; Myron J Levin; Curt R Freed; Christine L Wilcox; Gary H Cohen; Roselyn J Eisenberg; Lewis I Pizer
Journal:  J Neurovirol       Date:  2005-04       Impact factor: 2.643

10.  Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor.

Authors:  Guoying Zhou; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-22       Impact factor: 11.205

View more
  8 in total

Review 1.  Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Authors:  Balveen Kaur; E Antonio Chiocca; Timothy P Cripe
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

2.  Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor.

Authors:  Kenji Nakano; Masatoshi Kobayashi; Kei-ichiro Nakamura; Takeshi Nakanishi; Ryutaro Asano; Izumi Kumagai; Hideaki Tahara; Michihiko Kuwano; Justus B Cohen; Joseph C Glorioso
Journal:  Virology       Date:  2011-03-06       Impact factor: 3.616

3.  Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.

Authors:  Hiroaki Uchida; Marco Marzulli; Kenji Nakano; William F Goins; Janet Chan; Chang-Sook Hong; Lucia Mazzacurati; Ji Young Yoo; Amy Haseley; Hiroshi Nakashima; Hyunjung Baek; Heechung Kwon; Izumi Kumagai; Masahide Kuroki; Balveen Kaur; E Antonio Chiocca; Paola Grandi; Justus B Cohen; Joseph C Glorioso
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

Review 4.  Retargeting of herpes simplex virus (HSV) vectors.

Authors:  William F Goins; Bonnie Hall; Justus B Cohen; Joseph C Glorioso
Journal:  Curr Opin Virol       Date:  2016-09-08       Impact factor: 7.090

Review 5.  Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements.

Authors:  Su Shao; Xue Yang; You-Ni Zhang; Xue-Jun Wang; Ke Li; Ya-Long Zhao; Xiao-Zhou Mou; Pei-Yang Hu
Journal:  Front Mol Biosci       Date:  2022-02-28

6.  Designing Herpes Viruses as Oncolytics.

Authors:  Cole Peters; Samuel D Rabkin
Journal:  Mol Ther Oncolytics       Date:  2015-07-22       Impact factor: 7.200

Review 7.  Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells.

Authors:  Dhaval S Sanchala; Lokesh K Bhatt; Kedar S Prabhavalkar
Journal:  Front Pharmacol       Date:  2017-05-16       Impact factor: 5.810

Review 8.  Postexit surface engineering of retroviral/lentiviral vectors.

Authors:  Christoph Metzner; Feliks Kochan; John A Dangerfield
Journal:  Biomed Res Int       Date:  2013-04-17       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.